Sight Loss and Vision Priorities Report

Earlier this year, Birdshot Uveitis Society took part in the  Sight Loss and Vision Priority Setting Partnership which uniquely captured the views of patients, relatives, carers and eye health professionals to identify what research into sight loss and eye conditions should be addressing. It is rare that those with direct experience of conditions are able to influence the research agenda and we at BUS were delighted to participate.

Taking part in something like this is so important in helping to get a rare condition like Birdshot Uveitis better recognised.  It has really helped to get us on the map in terms of getting research done.   It is easy to forget that until very recently Birdshot Uveitis was considered incredibly rare affecting very few people.  By raising the profile and forming a network we are getting a better idea of the true picture.

If anyone wants a hard copy of the report sent to them they can get in touch with us or Fight for Sight to get their own copy.

The section you will probably want to look at is the ocular Inflammatory eye disease section( Page 31).  Many Thanks to our members who helped participate in this process.

A PDF of the report is attached here.

Top 10 Priorities for Ocular Inflammatory Diseases

The Sight Loss and Vision Priority Setting Partnership Survey in 2012 asked patients, carers and eye health professionals to identify unanswered questions about the prevention, diagnosis and treatment of sight loss and eye conditions that they wished to see answered. A number of Birdshot Uveitis Society members took part in this survey and raised many interesting questions.  Continue reading

Research News – May 2013

A recent paper (1) confirmed the previous finding  (2) of the involvement of the T helper 17 (th17) cells in birdshot. Th17 cells are associated with autoimmune diseases and are also involved in diseases such as ankylosing spondylitis and behcet disease (also associated with uveitis).

(1)Yang P, Foster CS. Interleukin 21, Interleukin 23, and Transforming Growth
Factor β1 in HLA-A29-Associated Birdshot Retinochoroidopathy. Am J Ophthalmol.
2013 Apr 23. doi:pii: S0002-9394(13)00168-2. 10.1016/j.ajo.2013.03.004.

(2)Kuiper JJ, Mutis T, de Jager W, de Groot-Mijnes JD, Rothova A. Intraocular
interleukin-17 and proinflammatory cytokines in HLA-A29-associated birdshot
chorioretinopathy. Am J Ophthalmol. 2011 Aug;152(2):177-182.e1. doi:
10.1016/j.ajo.2011.01.031.

The research  suggest the importance of systemic therapy and offer new insights into the potential of targeted treatments for Birdshot Uveitis.

 

What are your Birdshot priorities?

Last year many of you very kindly completed the Sight Loss and Vision Priority Setting Partnership survey and following this we have now received a short list of a number of “uncertainties” to consider.   We want to know which 10 “uncertainties”  are most important to you.  Please see below, ( or – Inflammatory FORM A_James Lind Alliance Sight Loss and Vision Priority Setting Partnership).  This is your chance to influence the direction taken by eye researchers on our behalf. Continue reading

What Is Your Experience of Having Birdshot?

A major survey is being undertaken across the UK and US into the experiences of people like us with Rare Diseases.  The findings of the research will guide future research and education, so if you can spare 10 minutes to complete the survey, please click on the link below or copy and paste it – once on the site, you will see the link for the survey: Continue reading

Sirolimus

Some of you may know that there have been trials on the drug, Sirolimus, which is given intravitreally or subconjunctivally (i.e. into the eye).

The idea behind this medication is that it should allow us to decrease our use of steroids which have such horrible side-effects, and it tends not to give so many other side effects, and it is not taken systemically (i.e. into our bodies). Continue reading